For best experience please turn on javascript and use a modern browser!
uva.nl

dr. L.P. (Lars) van der Heide

Faculty of Science
Swammerdam Institute for Life Sciences

Visiting address
  • Science Park 904
  • Room number: C2.204
Postal address
  • Postbus 94246
    1090 GE Amsterdam
  • Research

    1) The BCL2 code to dopaminergic development and Parkinson's disease

    Currently, there is no real cure for Parkinson's disease (PD), the second most common neurodegenerative disorder. Attenuating the rate of cell death would obviously be beneficial for PD patients, and key to understanding why dopaminergic neurons in the Substantia Nigra compacta (SNc) degenerate is understanding the genetic makeup that causes this predisposition. The answer may lie in the embryonic development of dopaminergic neurons in the SNc, which is coordinated by a multitude of both transcription and growth factors. This developmental program generates such a diversity that one could say that every adult neuron has its own identity and one cannot substitute for another. However, a major common denominator of developing dopaminergic neurons is that they undergo cell death when key transcription factors or growth factors are absent. We propose that these key transcription factors and growth factors control the expression of BCL2 proteins, proteins which directly control the balance between neuronal survival and death. By hijacking the BCL2 system controlling neuronal survival and death, neurodegeneration in PD may be therapeutically prevented and is the penultimate goal of this study.

    By using a Parkinson's disease mouse model and state of the art techniques we will identify the BCL2 factors expressed in dopaminergic neurons of the SNc and examine their individual contribution to neuronal survival. By manipulating the levels of the identified BCL2 factors and their upstream regulators we will identify novel targets to enhance dopaminergic viability which may serve as novel candidates for therapeutic intervention.

    BCL2 balance in dopaminergic development and Parkinson's disease (adapted from van der Heide and Smidt TMM 2013)

    The BCL2 code to dopaminergic development and Parkinson's disease

    van der Heide Lab
  • Master Molecular Neurosciences

    Molecular Neurosciences is part of the Master's programme Neurobiology.

    A basic understanding of molecular principles is the key for developing novel treatment paradigms for psychiatric and neurological diseases such as schizophrenia and Parkinson’s. The Master’s track in Molecular Neurosciences provides a training platform for students who have the ambition to play a major role in looking for solutions for the diseases of today and tomorrow.

    Study Molecular Neurosciences at the UVA

  • Publications

    2018

    2016

    2015

    • van der Heide, L. P., Wijchers, P. J. E. C., von Oerthel, L., Burbach, J. P. H., Hoekman, M. F. M., & Smidt, M. P. (2015). FoxK2 is required for cellular proliferation and survival. Journal of Cellular Physiology, 230(5), 1013-1023. https://doi.org/10.1002/jcp.24828 [details]

    2013

    2012

    • Hoekstra, E. J., von Oerthel, L., van der Linden, A. J. A., Schellevis, R. D., Scheppink, G., Holstege, F. C. P., ... Smidt, M. P. (2012). Lmx1a is an activator of Rgs4 and Gbr10 and is responsible for the correct specification of rostral and medial mdDA neurons. European Journal of Neuroscience, 37(1), 23-32. https://doi.org/10.1111/ejn.12022 [details]

    2016

    This list of publications is extracted from the UvA-Current Research Information System. Questions? Ask the library or the Pure staff of your faculty / institute. Log in to Pure to edit your publications. Log in to Personal Page Publication Selection tool to manage the visibility of your publications on this list.
  • Ancillary activities
    • http://macrobianbiotech.com/
      Founder and CEO